MMP9 and idiopathic pulmonary fibrosis: Further, andecaliximab, a monoclonal antibody against MMP-9, was developed at Gilead, which selectively binds to the allosteric site of MMP-9, reducing fibrosis in patients with idiopathic pulmonary fibrosis, particularly in patients with elevated levels of IFN-gamma (Table 1) [79].